INmune Bio (INMB) Stock Price

INmune Bio Price

NASDAQ·CLOSED
1.77USD+0.04 (+2.29 %)
Market closed

Over the last 4 years INmune Bio grew revenue by 8.8% annually, reaching 14,000.00 USD. For INmune Bio, the net margin of -300,000.0% is down versus -121,000.0% a few years ago. The consensus 12-month price target for INmune Bio is 5.61 USD, about 216.9% above where the stock trades today. Of 10 analysts, 8 rate the stock a buy — an overall Buy consensus. The stock trades about 58% above its 52-week low.

INmune Bio stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of INmune Bio over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how INmune Bio stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing INmune Bio's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

INmune Bio Stock Price History
DateINmune Bio Price
7/30/20261.77 USD
7/29/20261.73 USD
7/27/20261.67 USD
7/23/20261.72 USD
7/22/20261.84 USD
7/21/20261.97 USD
7/20/20261.99 USD
7/17/20261.90 USD
7/16/20262.07 USD
7/15/20262.07 USD
7/14/20262.02 USD
7/13/20261.86 USD
7/10/20261.94 USD
7/9/20261.79 USD
7/8/20261.70 USD
7/7/20261.74 USD
7/6/20261.68 USD
7/2/20261.70 USD
7/1/20261.68 USD
6/30/20261.63 USD
6/29/20261.62 USD
6/26/20261.42 USD
6/25/20261.49 USD
6/24/20261.35 USD
6/23/20261.42 USD
6/22/20261.38 USD
6/18/20261.45 USD
6/17/20261.30 USD
6/16/20261.28 USD
6/15/20261.28 USD
6/12/20261.24 USD
6/11/20261.27 USD
6/10/20261.21 USD
6/9/20261.22 USD
6/8/20261.24 USD
6/5/20261.26 USD
6/4/20261.35 USD
6/3/20261.32 USD
6/2/20261.42 USD
6/1/20261.39 USD
5/29/20261.41 USD
5/28/20261.42 USD
5/27/20261.40 USD
5/26/20261.43 USD
5/22/20261.45 USD
5/21/20261.44 USD
5/20/20261.41 USD
5/19/20261.41 USD
5/18/20261.49 USD
5/15/20261.55 USD
5/14/20261.74 USD
5/13/20261.46 USD
5/12/20261.39 USD
5/11/20261.35 USD
5/8/20261.43 USD
5/7/20261.43 USD
5/6/20261.52 USD
5/5/20261.54 USD
5/4/20261.48 USD
5/1/20261.51 USD
4/30/20261.43 USD
4/29/20261.33 USD
4/28/20261.40 USD
4/27/20261.47 USD
4/24/20261.39 USD
4/23/20261.37 USD
4/22/20261.43 USD
4/21/20261.37 USD
4/20/20261.49 USD
4/17/20261.45 USD
4/16/20261.34 USD
4/15/20261.32 USD
4/14/20261.26 USD
4/13/20261.24 USD
4/10/20261.18 USD
4/9/20261.28 USD
4/8/20261.29 USD
4/7/20261.27 USD
4/6/20261.23 USD
4/2/20261.21 USD
4/1/20261.23 USD
3/31/20261.13 USD
3/30/20261.14 USD
3/27/20261.12 USD
3/26/20261.20 USD
3/25/20261.22 USD
3/24/20261.18 USD
3/23/20261.24 USD
3/20/20261.17 USD
3/19/20261.22 USD
3/18/20261.24 USD
3/17/20261.28 USD
3/16/20261.35 USD
3/13/20261.31 USD
3/12/20261.33 USD
3/11/20261.42 USD
3/10/20261.28 USD
3/9/20261.31 USD
3/6/20261.33 USD
3/5/20261.27 USD
3/4/20261.32 USD
3/3/20261.40 USD
3/2/20261.33 USD
2/27/20261.29 USD
2/26/20261.34 USD
2/25/20261.39 USD
2/24/20261.34 USD
2/23/20261.26 USD
2/20/20261.31 USD
2/19/20261.32 USD
2/18/20261.35 USD
2/17/20261.40 USD
2/13/20261.44 USD
2/12/20261.47 USD
2/11/20261.57 USD
2/10/20261.60 USD
2/9/20261.54 USD
2/6/20261.51 USD
2/5/20261.42 USD
2/4/20261.52 USD
2/3/20261.55 USD
2/2/20261.58 USD
1/30/20261.59 USD
1/29/20261.56 USD
1/28/20261.61 USD
1/27/20261.80 USD
1/26/20261.67 USD
1/23/20261.70 USD
1/22/20261.70 USD
1/21/20261.64 USD
1/20/20261.60 USD
1/16/20261.73 USD
1/15/20261.63 USD
1/14/20261.54 USD
1/13/20261.50 USD
1/12/20261.47 USD
1/9/20261.49 USD
1/8/20261.53 USD
1/7/20261.58 USD
1/6/20261.56 USD
1/5/20261.49 USD
1/2/20261.54 USD
12/31/20251.56 USD
12/30/20251.60 USD
12/29/20251.66 USD
12/26/20251.73 USD
12/24/20251.77 USD
12/23/20251.70 USD
12/22/20251.88 USD
12/19/20251.83 USD
12/18/20251.82 USD
12/17/20251.83 USD
12/16/20251.89 USD
12/15/20251.91 USD
12/12/20252.01 USD
12/11/20252.14 USD
12/10/20252.23 USD
12/9/20252.17 USD
12/8/20252.04 USD
12/5/20251.91 USD
12/4/20251.88 USD
12/3/20251.76 USD
12/2/20251.57 USD
12/1/20251.57 USD
11/28/20251.74 USD
11/26/20251.65 USD
11/25/20251.52 USD
11/24/20251.48 USD
11/21/20251.51 USD
11/20/20251.49 USD
11/19/20251.51 USD
11/18/20251.50 USD
11/17/20251.46 USD
11/14/20251.42 USD
11/13/20251.43 USD
11/12/20251.52 USD
11/11/20251.51 USD
11/10/20251.58 USD
11/7/20251.63 USD
11/6/20251.63 USD
11/5/20251.77 USD
11/4/20251.72 USD
11/3/20251.80 USD
10/31/20251.83 USD
10/30/20251.73 USD
10/29/20251.82 USD
10/28/20251.82 USD
10/27/20251.84 USD
10/24/20251.90 USD
10/23/20251.79 USD
10/22/20251.78 USD
10/21/20251.89 USD
10/20/20251.92 USD
10/17/20251.85 USD
10/16/20251.85 USD
10/15/20251.93 USD
10/14/20251.87 USD
10/13/20251.83 USD
10/10/20251.86 USD
10/9/20251.98 USD
10/8/20252.01 USD
10/7/20251.96 USD
10/6/20252.06 USD
10/3/20252.08 USD
10/2/20252.14 USD
10/1/20252.13 USD
9/30/20252.07 USD
9/29/20252.11 USD
9/26/20252.01 USD
9/25/20252.03 USD
9/24/20251.95 USD
9/23/20251.99 USD
9/22/20251.98 USD
9/19/20251.90 USD
9/18/20251.97 USD
9/17/20251.91 USD
9/16/20251.99 USD
9/15/20251.97 USD
9/12/20252.01 USD
9/11/20251.97 USD
9/10/20251.76 USD
9/9/20251.78 USD
9/8/20251.81 USD
9/5/20251.95 USD
9/4/20251.92 USD
9/3/20251.97 USD
9/2/20251.97 USD
8/29/20252.03 USD
8/28/20252.09 USD
8/27/20252.05 USD
8/26/20252.16 USD
8/25/20252.24 USD
8/22/20252.41 USD
8/21/20252.35 USD
8/20/20252.36 USD
8/19/20252.40 USD
8/18/20252.53 USD
8/15/20252.53 USD
8/14/20252.45 USD
8/13/20252.56 USD
8/12/20252.42 USD
8/11/20252.40 USD
8/8/20252.56 USD
8/7/20252.79 USD
8/6/20252.76 USD
8/5/20252.69 USD
8/4/20252.86 USD
Access this data via the Eulerpool API
Get Free API Key

INmune Bio Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2022
370,000.00 USD
-25.95 M USD
-27.30 M USD
Jan 1, 2023
155,000.00 USD
-29.74 M USD
-30.01 M USD
Jan 1, 2024
14,000.00 USD
-43.00 M USD
-42.00 M USD
Jan 1, 2025 (e)
51,000.00 USD
-50.33 M USD
-52.07 M USD
Jan 1, 2026 (e)
0.00 USD
-31.41 M USD
-24.88 M USD
Jan 1, 2027 (e)
6.82 M USD
-36.42 M USD
-26.40 M USD
Jan 1, 2028 (e)
31.58 M USD
-33.49 M USD
-21.16 M USD
Jan 1, 2029 (e)
100.73 M USD
36.28 M USD
27.39 M USD

INmune Bio Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 1, 2026, 9:08 PM
 
REVENUEM USD
REVENUE GROWTH%
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
2016201720182019202020212022202320242025e2026e2027e2028e2029e2030e2031e
–––––––––––6.0031.00100.00176.00265.00
––––––––––––416.67222.5876.0050.57
––-12.00-7.00-12.00-29.00-25.00-29.00-43.00-50.00-31.00-36.00-33.0036.0089.00–
–––––––––––-600.00-106.4536.0050.57–
––-12.00-7.00-12.00-30.00-27.00-30.00-42.00-52.00-24.00-26.00-21.0027.0067.00126.00
–––-41.6771.43150.00-10.0011.1140.0023.81-53.858.33-19.23-228.57148.1588.06
9.729.729.7410.2711.9916.1317.9317.9820.0020.0020.0020.0020.0020.0020.0020.00
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales INmune Bio generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue INmune Bio retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare INmune Bio's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares INmune Bio has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against INmune Bio's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

INmune Bio stock margins

The INmune Bio margin analysis displays the gross margin, EBIT margin, as well as the profit margin of INmune Bio. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for INmune Bio.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2020
0.00 %
-122,300.00 %
-121,000.01 %
Jan 1, 2021
0.00 %
-16,194.44 %
-16,855.56 %
Jan 1, 2022
0.00 %
-7,013.51 %
-7,378.38 %
Jan 1, 2023
0.00 %
-19,187.74 %
-19,360.00 %
Jan 1, 2024
0.00 %
-307,142.85 %
-300,000.00 %
Jan 1, 2025 (e)
0.00 %
-98,691.00 %
-102,105.60 %
Jan 1, 2026 (e)
0.00 %
- %
- %
Jan 1, 2027 (e)
0.00 %
-534.01 %
-387.07 %

INmune Bio Stock Revenue, EBIT, Earnings per Share

The INmune Bio earnings per share therefore indicates how much revenue INmune Bio has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2020
0.00 USD
-1.02 USD
-1.01 USD
Jan 1, 2021
0.01 USD
-1.81 USD
-1.88 USD
Jan 1, 2022
0.02 USD
-1.45 USD
-1.52 USD
Jan 1, 2023
0.01 USD
-1.65 USD
-1.67 USD
Jan 1, 2024
0.00 USD
-2.15 USD
-2.10 USD
Jan 1, 2025 (e)
0.00 USD
-2.52 USD
-1.96 USD
Jan 1, 2026 (e)
0.00 USD
-1.57 USD
-0.94 USD
Jan 1, 2027 (e)
0.26 USD
-1.82 USD
-0.99 USD

INmune Bio business model & stock analysis

INmune Bio, Inc. is an emerging biotechnology company specializing in the development of immunotherapies for previously incurable diseases. The company was founded in 2015 and is headquartered in La Jolla, California. The company was founded by Dr. RJ Tesi, who was previously a senior scientist at another biotech firm. Dr. Tesi and his research team were frustrated with the disappointing results of existing treatments for a variety of diseases, including cancer, Alzheimer's, and Parkinson's. They decided to explore a new type of immunotherapy that would better address the complexities of the immune system. After years of research and development, INmune Bio has successfully developed several drug candidates, some of which are already being tested in clinical trials. INmune Bio's business model focuses on the invention of safe, affordable, and easy-to-use immunotherapies based on NK and T cells. Their goal is to combat chronic inflammation, glial stress, and neurodegenerative diseases through the use of drug candidates. The company has established strong partnerships with academic and clinical partners both in the US and internationally. INmune Bio is expected to focus on the further development and approval of several groundbreaking therapy options in the coming years. INmune Bio is divided into two divisions: INKmune and XPro1595. The INKmune technology platform is focused on strengthening a key component of the immune system, namely natural killer cells (NK cells). NK cells play an important role in the destruction of abnormal cells such as cancer cells. The INKmune technology aims to support the immune system through a combination of drugs and host metabolism changes, not only applying to cancer cells but also to other diseases such as Alzheimer's. XPro1595 is a drug candidate that is able to stop the inflammatory process by specifically inhibiting the activity of microglia cells in the brain. These cells are activated in many diseases, such as Alzheimer's, autoimmune diseases, or traumatic brain injuries. XPro1595 is intended to slow down the progressive course of these diseases by inhibiting harmful inflammation. INmune Bio currently has one drug candidate in Phase 1b clinical trials, INKmune. INKmune is a novel drug that aims to support the immune system by activating natural killer cells (NK cells). It has been developed to induce a comprehensive immune response to tumors of any kind. XPro1595 has also been developed to be used in various diseases, including Alzheimer's and Parkinson's. The drug is currently in Phase 2 clinical trials. In conclusion, INmune Bio is a biotechnology company specializing in immunotherapies. Their two main divisions, INKmune and XPro1595, aim to modulate the immune system and combat inflammation to treat various diseases. INmune Bio already has drug candidates in clinical development and works closely with academic and clinical partners. The company is expected to expand its portfolio of innovative therapy options and seek approval for additional drugs in the coming years.

INmune Bio SWOT Analysis

Strengths

INmune Bio Inc possesses several key strengths that contribute to its competitive advantage and potential success in the market. These include:

  • Strong Research and Development (R&D) capabilities in the field of immunotherapy
  • Proprietary technologies and platforms that enable the development of innovative therapies
  • A highly skilled and experienced team of scientists and researchers
  • Strategic collaborations with leading academic institutions and industry partners
  • A robust intellectual property portfolio protecting its groundbreaking discoveries

Weaknesses

Despite its strengths, INmune Bio Inc faces certain weaknesses and challenges that could potentially hinder its growth and performance. These include:

  • Relatively small scale and limited resources compared to larger competitors
  • Dependency on successful clinical trials and regulatory approvals for product commercialization
  • Risk of potential delays or setbacks in research and development processes
  • Vulnerability to changes in healthcare policies, regulations, and reimbursement systems

Opportunities

INmune Bio Inc can capitalize on various opportunities within the industry to fuel its growth and establish a stronger market presence. These opportunities include:

  • Increasing demand for innovative immunotherapies addressing unmet medical needs
  • Rising prevalence of chronic diseases and age-related conditions, creating a larger patient pool
  • Emerging markets and international expansion opportunities
  • Potential for strategic partnerships, licensing agreements, and collaborations for product development

Threats

INmune Bio Inc must also be aware of potential threats and external factors that could impact its business operations and market standing. These threats include:

  • Intense competition from established pharmaceutical companies and emerging biotech firms
  • Uncertainty related to regulatory and legal frameworks governing the development and commercialization of new treatments
  • Economic downturns and financial market instability affecting investment and funding opportunities
  • Possible negative reactions from patients, healthcare providers, or the public regarding the safety or efficacy of its products

INmune Bio Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

INmune Bio historical P/E ratio, EBIT multiple, and P/S ratio

INmune Bio annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

INmune Bio shares outstanding

The number of shares of INmune Bio was 20 M in 2025. This indicates how many shares INmune Bio is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2020
11.99 M Stocks
Jan 1, 2021
16.13 M Stocks
Jan 1, 2022
17.93 M Stocks
Jan 1, 2023
17.98 M Stocks
Jan 1, 2024
20.00 M Stocks
Jan 1, 2025 (e)
20.00 M Stocks
Jan 1, 2026 (e)
20.00 M Stocks
Jan 1, 2027 (e)
20.00 M Stocks

Current INmune Bio forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
80.00 % (8)
Hold
20.00 % (2)
Sell
0.00 % (0)
12M Price Target
5.61
Last Price
1.75
Currency
USD
12M Return Potential
220.57 %
LTM Return
0 %

INmune Bio Earnings Estimates

DateEPS estimateRevenue EstimateQuarterly report
8/5/2026-0.21USD0.00USD2026 Q2
5/6/2026-0.21USD0.00USD2026 Q1
3/25/2026-0.27USD0.00USD2025 Q4
2/26/2026-0.27USD0.00USD2025 Q4
5/1/2024-0.60USD43,860.00USD2024 Q1
2/29/2024-0.45USD43,860.00USD2023 Q4
8/1/2023-0.62USD-USD2023 Q2
5/3/2023-0.55USD-USD2023 Q1
3/1/2023-0.49USD0.00USD2022 Q4
11/2/2022-0.54USD0.00USD2022 Q3

EESG©

Eulerpool ESG Scorecard© for the INmune Bio stock

31/100
34
Environment
25
Social
33
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy—
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions—
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

INmune Bio shareholder structure

% Name
4.21091%
BlackRock Institutional Trust Company, N.A.
BlackRock Institutional Trust Company, N.A.
3.60228%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
1.66096%
Geode Capital Management, L.L.C.
Geode Capital Management, L.L.C.
1.30598%
State Street Investment Management (US)
State Street Investment Management (US)
0.94363%
Susquehanna International Group, LLP
Susquehanna International Group, LLP
0.77610%
Raymond James Financial Services Advisors, Inc.
Raymond James Financial Services Advisors, Inc.
...

INmune Bio Executives and Management Board

DM

Mr. David Moss

(54)

President, Chief Executive Officer

Compensation2.72 M USD
PL

Prof. Mark Lowdell

(62)

Chief Scientific Officer

Compensation1.79 M USD
MA

Ms. Marcia Allen

(74)

Independent Director

Compensation293,598.00 USD
JG

Mr. J. Kelly Ganjei

(52)

Independent Director

Compensation293,598.00 USD
SJ

Mr. Scott Juda

(54)

Independent Director

Compensation293,598.00 USD

INmune Bio Supply Chain

INmune Bio Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
1 companies
#Name1M3M6M1Y2YTrend
1
Xencor
Supplier
0.66
0.51
0.77
0.48
0.37

Frequently asked questions about INmune Bio

INmune Bio Inc is a pharmaceutical company specializing in developing innovative therapies to enhance the innate immune system for treating cancer and neurodegenerative diseases. Founded in 2015, INmune Bio has gained recognition for its focus on personalized medicine and pioneering solutions. The company aims to revolutionize the field of immunotherapy using its proprietary technologies, such as the DN-TNF vaccine, which targets tumor growth and reduces inflammation. With a strong commitment to research and development, INmune Bio is devoted to improving patient outcomes and tackling unmet medical needs. This dedication has positioned the company as a key player in the biotechnology industry.

All fundamentals and in-depth analysis of INmune Bio

Our stock analysis for INmune Bio stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of INmune Bio. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

INmune Bio Stock
INmune Bio Revenue→
INmune Bio Stock
INmune Bio Net Income→
INmune Bio Stock
INmune Bio P/E→
INmune Bio Stock
INmune Bio P/S→
INmune Bio Stock
INmune Bio EBIT→
INmune Bio Stock
INmune Bio Dividend→
INmune Bio Stock
INmune Bio Directors Dealings→
INmune Bio Stock
INmune Bio Stocks→
INmune Bio Stock
INmune Bio Market capitalization→
INmune Bio Stock
INmune Bio Debt→
INmune Bio Stock
INmune Bio Liabilities→
INmune Bio Stock
INmune Bio Equity→
INmune Bio Stock
INmune Bio AAQS→
INmune Bio Stock
INmune Bio Employees→
INmune Bio Stock
INmune Bio ROE→
INmune Bio Stock
INmune Bio ROA→
INmune Bio Stock
INmune Bio ROCE→
INmune Bio Stock
INmune Bio News→
INmune Bio Stock
INmune Bio Analyst Price Targets→

Health Stocks

Innate PharmaInmodeInnate PharmaInMed PharmaceuticalsInner Mongolia Furui Medical Science CoINKON Life Technology CoInnoCare PharmaInitiator Pharma A/SInnoCare PharmaINIFY LaboratoriesInnopharmaxInhibrx BiosciencesAll Stocks A–Z →